Posts

Hansoh Hits Phase III SCLC Goal

on

Henlius Advances First-in-Class B7-H3 Sialidase Fusion Protein HLX316/E-688 into First-in-Human Phase 1 Trial in China

on

FDA Lifts Partial Hold on Merck and Daiichi Sankyo's B7-H3 ADC Trial for Lung Cancer[6]

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Daiichi and Merck's Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

on

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

on